UltraSight

Private

IsraelHealthcare & Life Scienceshttps://ultrasight.com

Last Round

Series B

May 11, 2021

Total Funding Raised

$15M

Company Overview

UltraSight is a health tech company that provides an AI-powered software platform to guide medical professionals in acquiring cardiac ultrasound images.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Medical AI, Medical Devices, Healthcare Analytics

Business Model

B2B

Customer Profile

Hardware + Subscription, Subscription SaaS, Government Contracts, Services & Consulting

AI Layer

Application

Keywords

AI-guided ultrasoundcardiac ultrasoundpoint-of-care ultrasoundPOCUSultrasound guidancemedical imaging AISoftware as a Medical DeviceSaMDechocardiographyreal-time guidancecomputer visionpoint of care diagnosticsdigital healthcardiac imagingFDA clearance

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

UltraSight Comparables

Compare UltraSight with similar companies based on industry and business-model similarity.

UltraSight comparables — related companies by embedding similarity
Company	Similarity	Market Cap
GE HealthCare Technologies Inc.	81%
Exo	78%
ThinkSono	78%

View all Comparables

UltraSight Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	May 11, 2021
Series A	Mar 19, 2019

View all Funding Rounds

Key People

Founding team and executive leadership

Itay Kezurer

Co-Founder CTO

Founding Team

Davidi Vortman

Chief Executive Officer

Executive Team

Ramya Singh

Chief Commercial Officer

Executive Team

UltraSight Investors

Notable investors and investment history

UltraSight investors
Investor	Rounds
Weizmann Institute of Science	Series B
Keywest Global Investments	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 3, 2026
Presented at the 2026 Technology and Heart Failure Therapeutics (THT) Conference.
Mar 3, 2026
PVAD IQ study results presented at the 2026 THT Conference.

View all signals

UltraSight Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

UltraSight Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersIsrael

Employee Range43

Year Founded2018

Last FundingMay 11, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?